Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Pro-cellular survival and neuroprotection of citrus flavonoid: the actions of hesperetin in PC12 cells.

Authors: Hwang, SL  Lin, JA  Shih, PH  Yeh, CT  Yen, GC 
Citation: Hwang SL, etal., Food Funct. 2012 Oct;3(10):1082-90. Epub 2012 Jul 6.
Pubmed: (View Article at PubMed) PMID:22767158
DOI: Full-text: DOI:10.1039/c2fo30100h

Hesperetin protects cells against oxidative stress by diverse mechanisms including receptor-mediated actions. PGC-1alpha and seladin-1 provide potential targets for intervention in oxidative stress-associated neurodegeneration. PC12 cells express TrkA and estrogen receptor (ER). It is known that TrkA triggers the MAPK/ERK1, PI-3 K/Akt, PLCgamma/PKC and cAMP/PKA pathways, and membrane ER triggers the MAPK/ERK1, PKA, Akt/PKB or PKC pathway. Using PC12 cells and immunoblotting, we show that hesperetin induces the rapid (15 min) and sustained (~24 h) expression of PGC-1alpha (regulated by CREB) and seladin-1 (regulated by ER); hesperetin activates PI-3 K, PKA, PKC, ERK1 and CREB, and it induces PI-3 K, PKA, PGC-1alpha and seladin-1 via both ER and TrkA; any inhibitor of PI-3 K, PKA or PKC effectively suppresses the activation of ERK1 and CREB as well as the induction of PGC-1alpha and seladin-1; ERK1 inhibitors effectively suppress hesperetin-induced CREB activation and PGC-1alpha expression, but have no effect on the induction of seladin-1. This study reveals that hesperetin triggers ER- and TrkA-mediated parallel pathways, collaborating to induce proteins regulated by different transcriptional factors. This novel mechanism explains why hesperetin, although it is known to have relatively low antioxidant and estrogen activities, can exhibit multiple neuroprotective effects.

Annotation

Gene Ontology Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 7242166
Created: 2013-03-27
Species: All species
Last Modified: 2013-03-27
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.